Human Oncology Pipeline

Precision medicine services for individual blood cancer patients and CRO services for pharmaceutical companies screening a successful drug candidate

STAGE

R&D

COMMERCIAL

Service

Indication/Type

Tech Development

Clinical Study

Innovative Tech Approval

Approval

Sales

IMK-NL-1

Non-Hodgkin lymphoma treatment selection

IMK-MM-1

Multiple myeloma (MM) treatment selection

IMK-AML-1

Acute myeloid leukemia treatment selection

IMK-DS

Antibody drug conjugates screening and ex vivo efficacy test

IMK-NL-1

Non-Hodgkin lymphoma treatment selection

IMK-MM-1

Multiple myeloma (MM) treatment selection

IMK-AML-1

Acute myeloid leukemia treatment selection

IMK-DS

Antibody drug conjugates screening and ex vivo efficacy test

IMK-NL-1

Non-Hodgkin lymphoma treatment selection

IMK-MM-1

Multiple myeloma (MM) treatment selection

IMK-AML-1

Acute myeloid leukemia treatment selection

IMK-DS

Antibody drug conjugates screening and ex vivo efficacy test

Current

Plan by Q3 of 2024

Coming Soon – Early 2023

Personalized Prediction Profile for Canine Lymphoma and Leukemia

We measure how your dog's live cancer cells respond to different anticancer drugs. Then we use artificial intelligence (AI) to combine these measurements with other biological information to predict which drugs are most likely to be effective for your dog's lymphoma or leukemia.

Our mission is to empower clinicians and help patients with the best predictive information for personalized cancer care.

Our Milestones

2018

Opened ImpriMed Korea office
Received seed funding

2019

Received the Korean Venture Accreditation
Admitted to the Seoul Startup Hub

2020

Acquired IRB approval for the R&D on precision medicine technology for human blood cancer
Received a research grant ($370,000) from the Seoul Business Administration

2021

Won 4th place in the AI model development national competition held by the Ministry of Science and ICT in Korea
Received the research grant ($280,000) from the National Industry Promotion Agency
Nominated as one of the Top 100 Korean AI start-ups
Filed 3rd patent titled Predicting Clinical Outcome or Prognosis of Cancer Treatment based on Machine Learning
Received a research grant ($80,000) from the National Research Foundation of Korea

2022

Signed MOU with The Catholic University Seoul St. Mary's Hospital
Selected to the Mayo Clinic Platform Accelerate Program 2022
Presenting our AI precision medicine technology for newly diagnosed multiple myeloma patients at the International Myeloma Society 2022

Today

ImpriMed is bringing together our expertise in humans and canines to accelerate the development of AI-driven personalized medicine solutions for all cancer patients.